Morphologic and Immunophenotypic Markers as Surrogate Endpoints of Tamoxifen Effect for Prevention of Breast Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Morphologic and Immunophenotypic Markers as Surrogate Endpoints of Tamoxifen Effect for Prevention of Breast Cancer

Published:2005-11-02 Issue:3 Volume:94 Page:205-211
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Mohsin Syed K.,Allred D. Craig,Osborne C. Kent,Cruz Anatolio,Otto Pamela,Chew Helen,Clark Gary M.,Elledge Richard M.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-005-4896-1.pdf

Reference34 articles.

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467

2. B Fisher, J Costantino, DL Wickerham, C Redmond, MT Kavanah, WM Cronin, V Vogel, A Robidoux, NV Dimitrov, J Atkins, M Daly, S Wieand, E Tan-Chiu, L Ford and N Wolmark, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388

3. JA Hage van der, C Velde van de, J-P Julien, M Tubiana-Hulin, C Vandervelden and L Duchateau, Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19 (2001) 4224-4237

4. B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, RG Margolese, AB Cruz Jr., ER Fisher, DL Wickerham, N Wolmark, A DeCillis, JL Hoehn, AW Lees and NV Dimitrov, Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493

5. ATAC, Trialist's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. The Lancet 359: 2131–2139, 2002

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor–Negative Breast Cancer Chemoprevention;European Journal of Breast Health;2023-10-01

2. Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study;Cancer Prevention Research;2020-06-08

3. Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer;Cancer Prevention Research;2015-09-21

4. Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer;Cancer Prevention Research;2011-11-18

5. Breast Cancer Prevention Trials: Large and Small Trials;Seminars in Oncology;2010-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3